Pharmacodynamic substances and mechanism of Chelidonii Herba-Corydalis Rhizoma against estrogen receptor-positive breast cancer
- VernacularTitle:白屈菜-元胡药对抗雌激素受体阳性乳腺癌药效物质及作用机制
- Author:
Xiang ZOU
1
;
Qi SHU
1
;
Shuang WU
2
;
Jiahui YU
1
;
Xuerui ZHANG
1
;
Yuheng SUN
1
;
Zhongyuan QU
2
Author Information
1. Pharmaceutical Engineering Technology Research Center，Harbin University of Commerce，Harbin 150076，China
2. College of Pharmacy，Harbin University of Commerce，Harbin 150076，China
- Publication Type:Journal Article
- Keywords:
Chelidonium majus;
Corydalis yanhusuo;
estrogen receptor-positive breast cancer;
UPLC-Q-TOF-MS/MS
- From:
China Pharmacy
2023;34(8):935-940
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the main components of Chelidonii Herba-Corydalis Rhizoma （CHCR）， and to predict pharmacodynamic substances against estrogen receptor （ER） -positive breast cancer and their potential targets and signaling pathways， followed by verifying experiments. METHODS The ethanol extract of CHCR was analyzed by ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry （UPLC-Q-TOF-MS/MS）. The network pharmacology analysis was performed for the screened components. The network diagram of CHCR “active components-target-pathway” was constructed， and the enrichment pathway in vitro was validated. RESULTS A total of 58 chemical components were identified， including 57 alkaloids and 1 organic acid. A total of 38 active ingredients were screened from the network pharmacology， and 38 core targets were found in the protein-protein interaction network of “component-disease” intersection targets； 258 gene ontology entries and 137 Kyoto encyclopedia of genes and genomics pathways were obtained， mainly including estrogen signal pathway， phosphatidylinositol-3-kinase/protein kinase B （PI3K/Akt） signal pathway， etc. The results of validation test showed that the median inhibitory concentration of CHCR to MCF-7 cells was 693 μg/mL； 150， 300， 600 μg/mL CHCR could significantly reduce the expressions of phosphorylated PI3K， phosphorylated Akt， ERα protein and ESR1 mRNA （P＜0.01）. CONCLUSIONS The anti-ER-positive breast cancer effect of CHCR may be related to the regulation of ER and PI3K/Akt pathways， which has the characteristics of multi-component and multi-target effects.
